Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
Immunovia (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, has announced a webcast scheduled for March 24, 2025, at 3 pm CET to present additional results from their successful VERIFI clinical validation study. The study results, initially published on March 19, 2025, were positive for their next-generation pancreatic cancer test.
CEO Jeff Borcherding and VP Clinical and Medical Affairs Dr. Norma Alonzo Palma will lead the English-language presentation, which will include a Q&A session. The company focuses on developing blood-based testing to detect proteins and antibodies indicating high-risk pancreatic cancer cases.
Immunovia estimates that 1.8 million individuals in the USA, their largest target market, are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia (IMMNOV: Nasdaq Stockholm), un'azienda specializzata nella diagnostica del cancro pancreatico, ha annunciato un webcast programmato per il 24 marzo 2025, alle 15:00 CET, per presentare ulteriori risultati del loro riuscito studio di validazione clinica VERIFI. I risultati dello studio, pubblicati inizialmente il 19 marzo 2025, sono stati positivi per il loro test di nuova generazione per il cancro pancreatico.
Il CEO Jeff Borcherding e il VP Affari Clinici e Medici Dr. Norma Alonzo Palma condurranno la presentazione in lingua inglese, che includerà una sessione di domande e risposte. L'azienda si concentra sullo sviluppo di test basati sul sangue per rilevare proteine e anticorpi che indicano casi di cancro pancreatico ad alto rischio.
Immunovia stima che 1,8 milioni di individui negli USA, il loro mercato target più grande, siano ad alto rischio di cancro pancreatico e potrebbero beneficiare di test di sorveglianza annuali.
Immunovia (IMMNOV: Nasdaq Stockholm), una empresa de diagnóstico del cáncer pancreático, ha anunciado un webcast programado para el 24 de marzo de 2025, a las 15:00 CET, para presentar resultados adicionales de su exitoso estudio de validación clínica VERIFI. Los resultados del estudio, publicados inicialmente el 19 de marzo de 2025, fueron positivos para su prueba de cáncer pancreático de nueva generación.
El CEO Jeff Borcherding y la VP de Asuntos Clínicos y Médicos, Dra. Norma Alonzo Palma, liderarán la presentación en inglés, que incluirá una sesión de preguntas y respuestas. La empresa se centra en desarrollar pruebas basadas en sangre para detectar proteínas y anticuerpos que indican casos de cáncer pancreático de alto riesgo.
Immunovia estima que 1.8 millones de individuos en EE. UU., su mayor mercado objetivo, están en alto riesgo de cáncer pancreático y podrían beneficiarse de pruebas de vigilancia anuales.
Immunovia (IMMNOV: Nasdaq Stockholm), 췌장암 진단 회사가 2025년 3월 24일 오후 3시 CET에 VERIFI 임상 검증 연구의 추가 결과를 발표하기 위한 웹캐스트를 예정하고 있다고 발표했습니다. 연구 결과는 2025년 3월 19일에 처음 발표되었으며, 차세대 췌장암 검사에 대해 긍정적이었습니다.
CEO 제프 보르체르딩과 임상 및 의료 담당 부사장 노르마 알론조 팔마 박사가 영어 발표를 이끌며, 질문과 답변 세션도 포함될 것입니다. 이 회사는 고위험 췌장암 사례를 나타내는 단백질과 항체를 탐지하기 위해 혈액 기반 검사를 개발하는 데 주력하고 있습니다.
Immunovia는 미국에서 180만 명의 개인이 췌장암 고위험군에 해당하며, 연간 감시 검사를 통해 혜택을 볼 수 있다고 추정하고 있습니다.
Immunovia (IMMNOV: Nasdaq Stockholm), une entreprise spécialisée dans le diagnostic du cancer du pancréas, a annoncé un webinaire prévu le 24 mars 2025 à 15h00 CET pour présenter des résultats supplémentaires de leur étude de validation clinique VERIFI réussie. Les résultats de l'étude, publiés initialement le 19 mars 2025, étaient positifs pour leur test de nouvelle génération pour le cancer du pancréas.
Le PDG Jeff Borcherding et la VP des affaires cliniques et médicales, Dr. Norma Alonzo Palma, dirigeront la présentation en anglais, qui comprendra une session de questions-réponses. L'entreprise se concentre sur le développement de tests basés sur le sang pour détecter des protéines et des anticorps indiquant des cas de cancer du pancréas à haut risque.
Immunovia estime que 1,8 million d'individus aux États-Unis, leur plus grand marché cible, sont à haut risque de cancer du pancréas et pourraient bénéficier de tests de surveillance annuels.
Immunovia (IMMNOV: Nasdaq Stockholm), ein Unternehmen für die Diagnostik von Bauchspeicheldrüsenkrebs, hat ein Webcast für den 24. März 2025 um 15:00 Uhr CET angekündigt, um zusätzliche Ergebnisse aus ihrer erfolgreichen VERIFI klinischen Validierungsstudie zu präsentieren. Die Studienergebnisse, die ursprünglich am 19. März 2025 veröffentlicht wurden, waren positiv für ihren Test der nächsten Generation auf Bauchspeicheldrüsenkrebs.
CEO Jeff Borcherding und VP für klinische und medizinische Angelegenheiten, Dr. Norma Alonzo Palma, werden die Präsentation in englischer Sprache leiten, die eine Fragen-und-Antworten-Runde umfassen wird. Das Unternehmen konzentriert sich auf die Entwicklung von blutbasierten Tests zur Erkennung von Proteinen und Antikörpern, die auf Hochrisikofälle von Bauchspeicheldrüsenkrebs hinweisen.
Immunovia schätzt, dass 1,8 Millionen Personen in den USA, ihrem größten Zielmarkt, ein hohes Risiko für Bauchspeicheldrüsenkrebs haben und von jährlichen Überwachungsuntersuchungen profitieren könnten.
- None.
- None.
Jeff Borcherding, Immunovia CEO and Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs will present additional study results and share implications of the study.
The webcast will be held in English and will offer attendees the opportunity to ask questions. Here is the link to join the webcast:
https://access.creomediamanager.com/registration/5a1817e6-d829-4839-bbb7-67368c517927?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F5a1817e6-d829-4839-bbb7-67368c517927
A recording of the presentation will be available on Immunovia's website following the webcast.
For further information, please contact:
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-to-host-a-webcast-to-share-more-data-from-the-successful-verifi-clinical-validation-study-302407990.html
SOURCE Immunovia AB
FAQ
When is Immunovia's VERIFI study webcast and what will it cover?
What is the market potential for Immunovia's (IMMNOV) pancreatic cancer test in the USA?
What type of diagnostic test is Immunovia (IMMNOV) developing?
When did Immunovia (IMMNOV) announce the VERIFI study results?
Who will present at Immunovia's March 2025 VERIFI study webcast?
